Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).

Stopped early · Phase 1

Conditions studied: Purpura, Thrombocytopenic, Idiopathic

In brief

BI 655064 will be administered subcutaneously once weekly in patients with immune thrombocytopenic purpura (ITP) for up to 12 weeks.

Key facts

Study ID

NCT02009761

Run by

Boehringer Ingelheim

People needed

6

Starts

2013-12-18

Expected to finish

2016-04-26

Last updated by the study team

2024-03-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female chronic immune ITP patients

You may not qualify if…

• Any treatment of ITP excluded except for a stable dose of corticosteroids (up to 20 mg)

Where it is running

• University of Southern California — Los Angeles, California, United States
• New York Hospital, Cornell Medical Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.